Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozino propanedilo monohidratas - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotikai, vartojami diabetu - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. be kitų vaistų, skirtų gydyti 2 tipo cukrinis diabetas. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozino propanedilo monohidratas - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotikai, vartojami diabetu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. be kitų vaistų, skirtų gydyti 2 tipo cukrinis diabetas. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotikai, vartojami diabetu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

zakłady farmaceutyczne polpharma s.a. - dapagliflozinas - plėvele dengtos tabletės - 5 mg - dapagliflozin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

zakłady farmaceutyczne polpharma s.a. - dapagliflozinas - plėvele dengtos tabletės - 10 mg - dapagliflozin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

polta, uab - dapagliflozinas - plėvele dengtos tabletės - 5 mg - dapagliflozin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

polta, uab - dapagliflozinas - plėvele dengtos tabletės - 10 mg - dapagliflozin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - dapagliflozinas - plėvele dengtos tabletės - 5 mg - dapagliflozin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - dapagliflozinas - plėvele dengtos tabletės - 10 mg - dapagliflozin